The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
ABBVIE INC.COM00287Y10988810,000SH SOLE 10,00000
ACHILLION PHARMACEUTICALS INCCOM00448Q2019,5942,136,800SH SOLE 2,136,80000
ADVAXIS INCCOM NEW0076242081,417339,180SH SOLE 339,18000
APRICUS BIOSCIENCES INCCOM NEW03832V3072,4751,447,906SH SOLE 1,447,90600
BIOGEN INCCOM09062X103120,193383,858SH SOLE 383,85800
BIOVERATIV INCCOM09075r10066,4861,165,000SH SOLE 1,165,00000
INNOVIVA INCCOM45781M10150,8413,600,705SH SOLE 3,600,70500
MEDICINES COCOM58468810564,8941,752,000SH SOLE 1,752,00000
NOVELION THERAPEUTICS INCCOM NEW67001K2027,2051,025,000SH SOLE 1,025,00000